PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32867117-6	2020	The potency of codeine and loperamide is strongly dependent on the individual enzymatic activity of CYP2D6 and CYP3A4, as well as P-glycoprotein function.	Loperamide	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117	
31299239-6	2019	In vitro, axitinib inhibited loperamide metabolism with the IC50 of 18.34 muM for RLM, 1.705 muM for HLM and 1.604 muM for CYP3A4*1, and it was confirmed as a non-competitive inhibitor in all enzymes.	Loperamide	29-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129	
31571937-0	2019	Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro.	Loperamide	75-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36	
31571937-2	2019	Loperamide, identified as a CYP3A4 substrate, is prone to misuse and abuse and has high risks of life-threatening cardiotoxicity.	Loperamide	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34	
31571937-3	2019	Methods: Thus, this study is designed to evaluate the enzymatic characteristics of 29 CYP3A4 alleles toward loperamide in vitro, including the 7 novel CYP3A4 variants (*28-*34).	Loperamide	108-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92	
31571937-6	2019	Conclusion: As the first study to identify the properties of these CYP3A4 variants toward loperamide metabolism, our investigation may establish the genotype-phenotype relationship for loperamide, predict an individual"s capability in response to loperamide, and provide some guidance of clinical medication and treatment for loperamide.	Loperamide	90-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73	
31571937-6	2019	Conclusion: As the first study to identify the properties of these CYP3A4 variants toward loperamide metabolism, our investigation may establish the genotype-phenotype relationship for loperamide, predict an individual"s capability in response to loperamide, and provide some guidance of clinical medication and treatment for loperamide.	Loperamide	185-195	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73	
31571937-6	2019	Conclusion: As the first study to identify the properties of these CYP3A4 variants toward loperamide metabolism, our investigation may establish the genotype-phenotype relationship for loperamide, predict an individual"s capability in response to loperamide, and provide some guidance of clinical medication and treatment for loperamide.	Loperamide	185-195	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73	
31571937-6	2019	Conclusion: As the first study to identify the properties of these CYP3A4 variants toward loperamide metabolism, our investigation may establish the genotype-phenotype relationship for loperamide, predict an individual"s capability in response to loperamide, and provide some guidance of clinical medication and treatment for loperamide.	Loperamide	185-195	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73	
31116446-3	2019	Cytochrome P-450 (CYP)2C8, CYP3A, and P-glycoprotein inhibitors can increase the plasma and central nervous system concentrations and radically alter the risk profile of loperamide.	Loperamide	170-180	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-32	
28594339-13	2019	Three patients were concomitantly taking cimetidine, which is known to cause inhibition of CYP3A4 and CYP2C8 leading to increased levels of loperamide.	Loperamide	140-150	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97	
29237391-3	2018	METHODS: It was found that, for CYP3A4/5 substrates such as midazolam, amprenavir and loperamide, in vitro metabolic clearance is generally lower in enterocytes compared to that of hepatocytes, which is consistent with the relative abundance of the enzyme between the intestine and liver.	Loperamide	86-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38	
29237391-7	2018	As expected, ketoconazole inhibited CYP3A4/5-mediated metabolite formation in enterocytes for midazolam, amprenavir and loperamide, suggesting that cryopreserved enterocytes may be useful in determining intestinal CYP3A inhibition parameters.	Loperamide	120-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42	
29237391-8	2018	Interestingly, elacridar, a P-gp inhibitor, suppressed metabolite formation in enterocytes for loperamide, a substrate of CYP3A4 and P-gp, suggesting that enterocytes in suspension do not have active P-gp efflux functions, and the suppression of metabolism in enterocytes is probably caused by inhibition of CYP3A4/5 by elacridar.	Loperamide	95-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-128	
18192961-8	2007	Loperamide is metabolized by the cytochrome P450 (CYP) system and is a substrate for the CYP3A4 isoenzyme.	Loperamide	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95	
18192961-9	2007	Concurrent administration with CYP3A4 inhibitors may elevate loperamide concentrations.	Loperamide	61-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37